- Home
- ZTEK vs IMA Comparison
ZTEK vs IMA Comparison
Compare ZTEK & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- IMA
- Stock Information
- Founded
- ZTEK 2008
- IMA 2019
- Country
- ZTEK Canada
- IMA United States
- Employees
- ZTEK N/A
- IMA N/A
- Industry
- ZTEK Major Chemicals
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZTEK Industrials
- IMA Health Care
- Exchange
- ZTEK Nasdaq
- IMA Nasdaq
- Market Cap
- ZTEK 89.3M
- IMA 92.2M
- IPO Year
- ZTEK N/A
- IMA N/A
- Fundamental
- Price
- ZTEK $0.85
- IMA $8.79
- Analyst Decision
- ZTEK
- IMA Buy
- Analyst Count
- ZTEK 0
- IMA 1
- Target Price
- ZTEK N/A
- IMA $30.00
- AVG Volume (30 Days)
- ZTEK 135.1K
- IMA 99.7K
- Earning Date
- ZTEK 11-13-2025
- IMA 11-15-2025
- Dividend Yield
- ZTEK N/A
- IMA N/A
- EPS Growth
- ZTEK N/A
- IMA N/A
- EPS
- ZTEK N/A
- IMA N/A
- Revenue
- ZTEK $678,078.00
- IMA $4,300,000.00
- Revenue This Year
- ZTEK N/A
- IMA N/A
- Revenue Next Year
- ZTEK N/A
- IMA N/A
- P/E Ratio
- ZTEK N/A
- IMA N/A
- Revenue Growth
- ZTEK 2519.47
- IMA N/A
- 52 Week Low
- ZTEK $0.62
- IMA $7.24
- 52 Week High
- ZTEK $1.84
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- ZTEK 52.77
- IMA N/A
- Support Level
- ZTEK $0.78
- IMA N/A
- Resistance Level
- ZTEK $0.90
- IMA N/A
- Average True Range (ATR)
- ZTEK 0.07
- IMA 0.00
- MACD
- ZTEK 0.01
- IMA 0.00
- Stochastic Oscillator
- ZTEK 74.27
- IMA 0.00
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.